NEONC TECHNOLOGIES HOLDINGS
NTHINASDAQTrading Snapshot
- Day Range
- $738.02 – $752.06
- 52-Week Range
- $3.01 – $12.99
- Volume
- $2.33B
- Avg Volume
- $2.32B
- Shares Outstanding
- 25.9M
- Next Earnings
- Oct 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $99,429
- Last Q Revenue
- $22,814
- P/E Ratio
- —
- P/S Ratio
- 1134.5x
- EPS (TTM)
- $-1.86
- Dividend Yield
- —
Why Investors Own NTHI
- ✓High-growth profile — revenue up +32.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 54% gross margin and 17% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About NEONC TECHNOLOGIES HOLDINGS
A company profile for NEONC TECHNOLOGIES HOLDINGS isn’t available yet — check back soon.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Mereo BioPharma Group (NASDAQ:MREO) stock increased by 21.7% to $0.33 during Tuesday's pre-market session. The market value of their outstanding shares is at $43.4 million. Organigram Global (NASDAQ:OGI)
NeOnc Technologies Q2 EPS $(0.58) Misses $(0.15) Estimate
NeOnc Technologies (NASDAQ:NTHI) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.15) by 286.67 percent. This is a 93.33 percent decrease over losses of $(0.30) per share
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-market session. The company's market cap stands at $3.3 million. Stereotaxis (AMEX:STXS) stock increased by 8.51%
NeOnc Technologies Receives Written Feedback From FDA Regarding CMC Development Program For NEO212, Temozolomide-Perillyl Alcohol Conjugate; Co. Cancels July Meeting
NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage life sciences company focused on the development of treatments for central nervous system cancers, today